Literature DB >> 23726130

Patterns of metastatic spread in early breast cancer.

M B Klevesath1, K Pantel, O Agbaje, E Provenzano, G C Wishart, P Gough, S E Pinder, S Duffy, A D Purushotham.   

Abstract

AIMS: The aim of this study was to prospectively investigate metastatic pathways of spread to lymph node versus bone marrow and identify biological characteristics that determine these patterns in early invasive breast cancer. PATIENTS AND METHODS: In all, 177 patients with early invasive breast cancer underwent surgical extirpation of the primary tumour with sentinel lymph node biopsy (SLNB). Bone marrow (BM) aspiration was performed to screen for cytokeratin-positive cells by immunocytochemistry. Lymphatic spread was assessed by histopathological examination of lymph nodes (LN). A representative subset of 87 tumours was analysed by tissue microarray (TMA) to evaluate expression of markers that potentially influence haematogenous vs. lymphatic spread. Patients were followed up for a median of 54.7 months.
RESULTS: Of the 177 patients, 114 (64%) were BM-/LN-, 38 (22%) BM-/LN+, 19 (11%) BM+/LN- and 6 (3%) BM+/LN+. Multivariate analysis of histopathological characteristics revealed that increasing tumour size was significantly associated with both LN positivity (p = 0.003) and BM positivity (p = 0.01), the presence of lymphovascular invasion significantly correlated with LN+ (p = 0.01), whereas lower histological grade was significantly associated with BM+ (p = 0.03). LN+ and BM+ were non-significantly negatively related to each other. Univariate analysis of the TMA data showed differential expression patterns for several factors; significant differences between effects on the two metastatic pathways (lymphatic vs. haematogenous) were found for expression of CD54 (p = 0.03), osteopontin (p = 0.04), bone sialoprotein (p = 0.04) and CXCR4 (p = 0.009). High expression of CD54, osteopontin and bone sialoprotein (BSP) was positively associated with BM + but was either not associated, or negatively associated, with LN+. High CXCR4 expression was positively associated with LN+ and negatively with BM+. High VEGF-C expression was associated with both LN+ and BM+, although this did not attain statistical significance. Due to the small number of clinical events during clinical follow-up, no associations were identified between metastatic spread patterns, recurrence and/or death.
CONCLUSION: These findings suggest that distinct lymphatic and haematogenous metastatic pathways exist in early breast cancer and that these pathways are governed by specific biological markers.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23726130     DOI: 10.1016/j.breast.2013.04.017

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  14 in total

1.  Development of novel murine mammary imaging windows to examine wound healing effects on leukocyte trafficking in mammary tumors with intravital imaging.

Authors:  Tammy Sobolik; Ying-Jun Su; Will Ashby; David K Schaffer; Sam Wells; John P Wikswo; Andries Zijlstra; Ann Richmond
Journal:  Intravital       Date:  2016-01-13

2.  Immunohistochemical validation of overexpressed genes identified by global expression microarrays in adrenocortical carcinoma reveals potential predictive and prognostic biomarkers.

Authors:  Julian C Y Ip; Tony C Y Pang; Anthony R Glover; Patsy Soon; Jing Ting Zhao; Stephen Clarke; Bruce G Robinson; Anthony J Gill; Stan B Sidhu
Journal:  Oncologist       Date:  2015-02-05

3.  In breast cancer patients sentinel lymph node metastasis characteristics predict further axillary involvement.

Authors:  Ildiko Illyes; Anna-Maria Tokes; Attila Kovacs; A Marcell Szasz; Bela A Molnar; Istvan A Molnar; Ilona Kaszas; Zsuzsanna Baranyak; Zsolt Laszlo; Istvan Kenessey; Janina Kulka
Journal:  Virchows Arch       Date:  2014-05-09       Impact factor: 4.064

4.  Dehydroepiandrosterone inhibits events related with the metastatic process in breast tumor cell lines.

Authors:  Rebeca López-Marure; Estrella Zapata-Gómez; Leticia Rocha-Zavaleta; María Cecilia Aguilar; Magali Espinosa Castilla; Jorge Meléndez Zajgla; Noemí Meraz-Cruz; Claudia Huesca-Gómez; Ricardo Gamboa-Ávila; Erika Olivia Gómez-González
Journal:  Cancer Biol Ther       Date:  2016-06-03       Impact factor: 4.742

5.  Sentinel lymph node biopsy in breast cancer: predictors of axillary and non-sentinel lymph node involvement.

Authors:  Hakan Postacı; Baha Zengel; Ulkem Yararbaş; Adam Uslu; Nuket Eliyatkın; Göksever Akpınar; Fevzi Cengiz; Raika Durusoy
Journal:  Balkan Med J       Date:  2013-12-01       Impact factor: 2.021

Review 6.  Bone metastasis: the importance of the neighbourhood.

Authors:  Peter I Croucher; Michelle M McDonald; T John Martin
Journal:  Nat Rev Cancer       Date:  2016-05-25       Impact factor: 60.716

7.  Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients.

Authors:  Amina Maimaitiaili; Di Wu; Zhenyu Liu; Haimeng Liu; Xiamusiye Muyiduli; Zhimin Fan
Journal:  Cancer Biol Med       Date:  2018-08       Impact factor: 4.248

8.  CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways.

Authors:  Tammy Sobolik; Ying-Jun Su; Sam Wells; Gregory D Ayers; Rebecca S Cook; Ann Richmond
Journal:  Mol Biol Cell       Date:  2014-01-08       Impact factor: 4.138

9.  Stabilization of bone marrow infiltration by metastatic breast cancer with continuous doxorubicin.

Authors:  Gaurav Pahouja; Robert Wesolowski; Raquel Reinbolt; Gary Tozbikian; Michael Berger; Neha Mangini; Maryam B Lustberg
Journal:  Cancer Treat Commun       Date:  2015

10.  Heterogeneity of mesenchymal markers expression-molecular profiles of cancer cells disseminated by lymphatic and hematogenous routes in breast cancer.

Authors:  Aleksandra Markiewicz; Magdalena Książkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Jolanta Szade; Marzena Wełnicka-Jaśkiewicz; Anna J Zaczek
Journal:  Cancers (Basel)       Date:  2013-11-08       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.